An observational study in Arthritis, Rheumatoid, Arthritis, Psoriatic and Crystal Arthropathies, sponsored by Semmelweis University. Recruiting at 3 sites in Hungary. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-12-20.
Sponsored by Semmelweis University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 204 studies in Arthritis, Rheumatoid with a site in Hungary — 4 open to participants now, 11 under way, 2 of them phase 3. Arthritis, Rheumatoid · Hungary.
Among the 204 studies in Arthritis, Rheumatoid with a site in Hungary, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2022, is one of 11 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 193rd registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 204 studies in Arthritis, Rheumatoid with a site in Hungary are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Hungary, United States, Argentina and 14 more countries
Ages 18+
AbbVie · Sites in Hungary, United States, Canada and 9 more countries
Ages 18+
Polyclinic of the Hospitaller Brothers of St. John of God, Budapest · Sites in Hungary
Ages 40+
A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
204 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 90 · Phase 3 79 · Phase 4 12
First in 2002; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 350 across the 193 interventional studies, 353 across the 11 observational. Of the 192 that completed or were terminated, 142 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
198 of 204 have an industry lead sponsor. The 10 most frequent:
Semmelweis University is the lead sponsor of 140 studies on the registry; 55 are open to participants now.
Semmelweis University has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
5 of the studies in Arthritis, Rheumatoid with a site in Hungary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05391100Polyclinic of the Hospitaller Brothers of St. John of God, BudapestScreening of Patients With Rheumatoid Arthritis for Interstitial Lung Disease | 2026-12 |
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT05657847Semmelweis UniversityNovel Complex Radiodiagnostics of Peripherial Arthropathies | 2027-02-01 |
| NCT06754462Immunovant Sciences GmbHA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | 2027-09 |
| NCT07276581AstraZenecaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | 2027-11-12 |
Add all 5 to your calendar (.ics) → With an account.
Among the 204 studies in Arthritis, Rheumatoid with a site in Hungary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Chronic peripherial arthritides are common diseases with soaring public health consequences. Our goal is to assess the role of photon-counting detector computed tomography in the diagnostics of peripherial arthropathies.
Background:
Chronic peripherial arthritides include immune-mediated (rheumatoid arthritis, psoriatic arthritis) and crystal deposition diseases (gout, pseudogout, hydroxiapatite-deposition disease).
Conventional radiographs are utilized to screen arthritis-associated deformities, bone erosions and joint space narrowing. MRI is able to detect bone marrow edema, synovitis and the swelling of soft tissues. Sonography can also detect synovitis and soft tissue involvement but does not provide information about bone marrow edema and poorly assess erosions. Photon-counting detector computed tomography (PCD-CT) is a novel type of CT device which provides many advantages like improved signal-to-noise ratio, intrinsic spectral information, lower radiation exposure, and better spatial resolution. PCD-CT is a type of X-ray computed tomography in which X-rays are detected using a photon-counting detector. These detectors are able to directly transform X-ray photons into electrical signals. Compared to previous generation scintillation detectors, photon-counting detectors have several advantages: being able to count the charges created by individual x-ray photons and measuring their energy level also providing multi- energy spectral sensitivity. 0.2 mm slice thickness potentiates the detection of bone erosionss. Collagen-rich structures like cartilage, ligaments, and tendons are easier to identify on PCD-CT images. Bone marrow edema can be visualized with virtual non- calcium reconstruction. PCD-CT could both detect and differentiate cristal deposits.
Aims: To assess the possible role of PCD-CT technique in the diagnostics of peripherial arthropathies.To compare the role of PCD-CT in the detection of arthritis-related pathologies with other imaging modalities like MRI and conventional radiography.
Adults suffering from peripherial arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rheumatoid arthritis patients. (American College of Rheumatology (ACR) 1987, ACR/European League Against Rheumatism (EULAR) \>18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis (including RF, ACPA)
Device: Photon-counting detector-CT
Psoriatic arthritis patients. (CASPAR Criteria) \>18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis.
Device: Photon-counting detector-CT
Crystal arthropathies patients. \>18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis.
Device: Photon-counting detector-CT
CT scan
Bone erosions
To assess the detection of arthritis-related bone erosions with different imaging techniques, including PCD-CT.
Time frame: From baseline to at least 2 years
Bone marrow edema and periarticular soft tissue involvement
To assess the detection of arthritis-related bone marrow edema and periarticular soft tissue with different imaging techniques, including PCD-CT.
Time frame: From baseline to at least 2 years
Crystal deposit characterization
To detect the different crystal deposits with PCD-CT.
Time frame: From baseline to at least 2 years
To evaluate the performance of PCD-CT in the detection of active arthritis-related imaging findings and structural damages.
To compare the performance of PCD-CT with different modalities in the diagnostics of peripherial arthropathies.
Time frame: From baseline to at least 3 years
Plan to share: Undecided — Undecided
Started Mar 2022 (actual). Primary completion is estimated for Feb 2027, 58 months after the start.
Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 58 months is above that.
Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.